KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Taxes Dividends payables Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Pfizer (PFE) Liabilities from Discontinued Operations (2018 - 2019)

Pfizer (PFE) has disclosed Liabilities from Discontinued Operations for 6 consecutive years, with 2413000000.0 as the latest value for Q4 2019.

On a quarterly basis, Liabilities from Discontinued Operations rose 27.67% to 2413000000.0 in Q4 2019 year-over-year; TTM through Dec 2019 was 2413000000.0, a 27.67% increase, with the full-year FY2019 number at 2413000000.0, up 27.67% from a year prior.
Liabilities from Discontinued Operations was 2413000000.0 for Q4 2019 at Pfizer, up from 1935000000.0 in the prior quarter.
In the past five years, Liabilities from Discontinued Operations ranged from a high of 2413000000.0 in Q4 2019 to a low of 1890000000.0 in Q4 2018.